<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04992208</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-nCOV-MA4008</org_study_id>
    <nct_id>NCT04992208</nct_id>
  </id_info>
  <brief_title>Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents</brief_title>
  <official_title>Safety Observation of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Population Aged 3~17 Years : A Multicenter,Open-label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Research and Development Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center and open design, phase Ⅳ clinical trial of an inactivated&#xD;
      SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd.The&#xD;
      purpose of this study is to evaluate the safety of the SARS-CoV-2 Inactivated vaccine in&#xD;
      population aged 3~17 years and in people with pre-existing disease to provide reference for&#xD;
      improving the immunization strategy of COVID-19 vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multi-center and open design, phase Ⅳ clinical trial in population aged 3~17&#xD;
      years . The experimental vaccine will be manufactured by Sinovac Research and Development&#xD;
      Co.,Ltd.The study is planned to be carried out in 11 provinces from August 2021 to December&#xD;
      2022, including Liaoning, Heilongjiang, Anhui, Fujian, Jiangxi, Hubei, Guangxi, Chongqing,&#xD;
      Guizhou, Yunnan and Gansu. Each province will serve as a research center, and each research&#xD;
      center will select the corresponding research site.A total of 33000 subjects including&#xD;
      patients with pre-existing will be enrolled with 3000 for each research center, including 600&#xD;
      subjects aged 3~5years，1200 subjects aged 6~11 years,1200 subjects aged 12~17 years.&#xD;
&#xD;
      And subjects will receive two doses of vaccine on day 0 and day 28.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 24, 2021</start_date>
  <completion_date type="Anticipated">December 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 25, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety index 1-incidence of adverse reactions</measure>
    <time_frame>Within 0~7 days after each dose</time_frame>
    <description>Incidence rate of adverse reactions within 0~7 days after each dose in all populations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety index 2-incidence of adverse reactions</measure>
    <time_frame>Within 0-28 days after each dose vaccination</time_frame>
    <description>Incidence rate of adverse reactions within 0~28 days after each dose in all populations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety index 3-incidence of adverse reactions</measure>
    <time_frame>Within 0~7 days after each dose vaccination</time_frame>
    <description>Incidence of adverse reactions within 0~7 days after each dose in each age group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety index 4-incidence of adverse reactions</measure>
    <time_frame>Within 0~28 days after each dose vaccination</time_frame>
    <description>Incidence rate of adverse reactions within 0~28 days after each dose in each age group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety index 5-incidence of adverse reactions</measure>
    <time_frame>Within 0~7 days after each dose vaccination</time_frame>
    <description>Incidence of adverse reactions within 0~7 days after each dose in the population with pre-existing disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety index 6-incidence of adverse reactions</measure>
    <time_frame>Within 0~28 days after each dose vaccination</time_frame>
    <description>Incidence of adverse reactions within 0~28 days after each dose in the population with pre-existing disease.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33000</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All of the participants(N=33000) will receive two doses inactivated SARS-CoV-2 vaccine . Vaccine will given by intramuscular injection on day 0 and day 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Experimental Group</intervention_name>
    <description>SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection</description>
    <arm_group_label>Experimental Group</arm_group_label>
    <other_name>CoronaVac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have not received any COVID-19 vaccine in the past or at least one dose of CoronaVac&#xD;
             manufactured by Sinovac Research and Development Co.,Ltd;&#xD;
&#xD;
          -  Population aged 3~17 years ;&#xD;
&#xD;
          -  The subjects can understand and voluntarily sign the informed consent form and&#xD;
             participate in the follow-up;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of severe allergy to the vaccine such as acute allergic reaction,angioedema&#xD;
             and dyspnea ;&#xD;
&#xD;
          -  Severe neurological disease such as Myelitis transverse,Guillain-Barre Syndrome and&#xD;
             demyelinating disorders;&#xD;
&#xD;
          -  Acute disease,acute onset of chronic disease and severe chronic diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoqiang Liu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yunnan Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xing Fang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liaoning Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhaodan Sun</last_name>
    <role>Principal Investigator</role>
    <affiliation>HeilongjiangProvincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fubing Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hefei Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dongjuan Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fujian Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shicheng Guo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangxi Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yeqing Tong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hubei Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qiuyun Deng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangxi Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qing Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chongqing Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruizhi Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guizhou Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaoshu Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gansu Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoqiang Liu, Doctor</last_name>
    <phone>15911568282</phone>
    <email>lxq7611@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yongping Center for Diseases Control and Prevention</name>
      <address>
        <city>Dali</city>
        <state>Yunnan</state>
        <zip>650022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>XiaoQiang Liu</last_name>
      <email>lxq7611@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

